LXEO

Lexeo Therapeutics, Inc. Common Stock

5.66

USD

LXEO Earnings Reports

Positive Surprise Ratio

LXEO beat 5 of 9 last estimates.

56%

Next Report

Date of Next Report

Estimate for Q-- -- (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

Implied change from Q-- -- (Revenue/ EPS)

Lexeo Therapeutics, Inc. Common Stock earnings per share and revenue

On Mar 16, 2026, LXEO reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -0.32 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.35% price change (close before vs. close after earnings).

Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Context Therapeutics Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$0.10

Actual

-$0.14

Surprise

-29.39%

Avalo Therapeutics, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$1.49

Actual

-$1.12

Surprise

+24.33%

Journey Medical Corporation Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.05

Actual

-$0.04

Surprise

+31.86%

Surrozen, Inc. Common

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$1.21

Actual

Surprise

Achieve Life Sciences, Inc.

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.12%

Vivani Medical, Inc. Common Stock (DE)

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.10

Actual

-$0.09

Surprise

Pyxis Oncology, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$0.34

Actual

-$0.28

Surprise

+15.55%

Acrivon Therapeutics, Inc. Common Stock

Report Date

Mar 19, 2026 For Q4 25

Estimate

-$0.47

Actual

-$0.52

Surprise

-9.34%

Fractyl Health, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

$0.15

Surprise

+181.70%

NRX Pharmaceuticals, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

$0.00

Actual

-$0.01

Surprise

-361.54%

FAQ

What were Lexeo Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Lexeo Therapeutics, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.

How did the market react to Lexeo Therapeutics, Inc. Common Stock's Q4 2025 earnings?

The stock price moved down -1.35%, changed from $6.66 before the earnings release to $6.57 the day after.

When is Lexeo Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for --.

What are the forecasts for Lexeo Therapeutics, Inc. Common Stock's next earnings report?

Based on -- analysts, Lexeo Therapeutics, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.